Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medimetriks Pharmaceuticals, Inc
This is a multi-center, open-label study to assess the degree of systemic exposure and safety of MM36 1% ointment following 4 weeks of twice daily dosing under maximal-use conditions in pediatric subjects with atopic dermatitis.
Age
2–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects 2 to \<18 years of age
Diagnosis of atopic dermatitis (AD)
AD affecting ≥ 35% body surface area (BSA) if 2 to \< 12 years of age or ≥ 25% if subject is ≥ 12 years of age (excluding scalp and venous access areas)
You may not be if
Active or acute viral skin infection
History of recurrent bacterial infection
Malignancy
Clinically significant history or physical findings that may pose a health risk to subject or may have an impact on study assessments
Clareo Health | Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis
